Call for Speaker Proposals
第3回
Cancer Biologics
-抗癌生物製剤学会-
複合体、多特異性、バイオマーカー、および最新のアプローチ
2月21日〜23日
3年目を迎えるこの学会は、癌治療薬の創薬にまつわる重要な分野や新たな分野について学ぶことができる貴重な機会となっており、強力な標的設定機能やエフェクター機能を実現する最新の工学的アプローチから臨床前開発とトランスレーショナル研究、臨床的な進展といったテーマが取り上げられます。また、抗体薬物複合体、多特異性製品、併用療法、免疫療法、ワクチンなどにも光が当てられるほか、核酸生物製剤や癌幹細胞の標的化といった新しい分野に対応する最新のアプローチ、デリバリーと腫瘍浸透にまつわる課題を克服する手段なども検討されることになっています。
Who should attend: VPs, Directors, CEOs, CSOs and Scientists from Large Pharma, Biotechs and Academia in such fields as R&D, Product Development, Translational Medicine, Protein Engineering, Target Discovery
Topics will include, but are not limited to advances in the following:
- Advances with antibody-drug conjugates
- Bi- and multi-specific biotherapeutics
- Combination therapies
- Nucleic acid therapies (RNAi and siRNA)
- Immunotherapies, vaccines and adoptive T cell therapy
- Targeting cancer stem cells
- Identification of novel targets
- Novel engineering and platforms
- Penetration and delivery to solid tumors
- Translational and clinical biomarkers
- Pre-clinical and clinical advances
- Strategies for regulatory approval, licensing and success in the market
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
